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Saving lives and flattening the curve are the foremost priorities during the ongoing
pandemic spread of SARS-CoV-2. Developing cutting-edge technology and collating
available evidence would support frontline health teams. Nutritional adequacy improves
general health and immunity to prevent and assuage infections. This review aims to
outline the potential role of probiotics in fighting the COVID-19 by covering recent
evidence on the association between microbiota, probiotics, and COVID-19, the role
of probiotics as an immune-modulator and antiviral agent. The high basic reproduction
number (R0) of SARS-CoV-2, absence of conclusive remedies, and the pleiotropic effect
of probiotics in fighting influenza and other coronaviruses together favour probiotics
supplements. However, further support from preclinical and clinical studies and reviews
outlining the role of probiotics in COVID-19 are critical. Results are awaited from
many ongoing clinical trials investigating the benefits of probiotics in COVID-19. ©
2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights
reserved.
Key Words: Coronavirus, COVID-19, Immunity, Microbiota, Probiotics, SARS-CoV-2.

Introduction
The novel coronavirus pandemic of 2019 (COVID-19)
(1), an emerging infectious disease (EID) caused by
multiple strains of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2) has spread to 216 countries
and territories, with catastrophic impact on global health
and economy. As of 12th August 2020, there are 20.4 mil-
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lion cumulative confirmed cases of COVID-19, including
0.74 million deaths, with a case-fatality rate (CFR) of 3.6%
(2). Among WHO regions, the Americas and Europe have
the highest confirmed cases. Ten most affected countries
are the United States of America (USA), Brazil, India,
Russia, South Africa, Mexico, Peru, Colombia, Chile, and
Iran (3).
COVID-19 mortality rates vary significantly across
different countries. Currently, CFR has been higher in the
United Kingdom (14.8%), Italy (14.0%), France (12.4%),
Mexico (10.9%), Spain (8.7%) than in Brazil (3.3%), USA
(3.2%), India (2.0%), South Africa (1.9%) and Russia
(1.7%) (2), but the reasons for this variation remain
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ambiguous. Differences in virus strains, rate of COVID-19
testing, quality, and access to the healthcare system, and
preventive strategies are among the listed reasons (4,5).
Demographic characteristics such as the proportion of
elderly, dietary and lifestyle patterns, comorbidities, and
socioeconomic status, also influence the susceptibility,
severity, and fatality of COVID-19 (5).
Most COVID-19 cases are mild to moderate with
self-limiting respiratory illness. Geriatrics and individuals
with hypertension, diabetes, cardiac diseases, pulmonary
diseases, and cancer are extremely vulnerable to severe
COVID-19 (1). A meta-analysis with more than 50000
COVID-19 cases found a pooled incidence of 20.2% severity and 3.1% mortality (6). Inflammatory markers like creactive protein (CRP) and lymphocytopenia are significantly correlated with severity. The immune status of certain individuals seems to fight COVID-19 better than others (4). Most trials repurposing antivirals have not proven
effective so far. Moreover, a subset of patients develops a
potentially life-threatening hyperinflammatory state called
cytokine storm, accompanied by multi-organ dysfunction,
respiratory failure, and a clinically distinct hypercoagulable state of the pulmonary vasculature. COVID-19 requires a multidimensional therapeutic approach, ranging
from virus-targeted interventions in the early stages to
immunomodulation in late stages (7). While dexamethasone reduces the mortality rate in severe COVID-19 patients, it has limited value in mild disease (8). Besides,
WHO and many countries have advised caution in implementing steroid therapy in COVID-19 patients with comorbidities such as diabetes and hypertension (9). Suppressing the exaggerated immune response can protect the
lungs, but containing the infection needs a fully functional
immune system. Therefore, fine-tuning the host-microbiota
balance could be useful in COVID-19, especially with comorbidities. Considering the immunomodulatory (10), antiinflammatory (11), antioxidant (12), and antiviral (13) actions of probiotics, we hypothesize that a pleiotropic mechanism could be a preventive /curative option for COVID-19
(Figure 1).
Microbiota and Immunity
Microbiotas constitute the entire spectrum of microbial
communities residing in the host, such as bacteria, viruses,
fungi, and protozoans. The human body has more microbes than human cells, occupying mucosal membranes,
and the skin. The human microbiota’s role in shaping
the immunity and preserving homeostasis has been extensively studied, particularly in the gut, where microbes
are most abundant (14). Germ-free mice have demonstrated the protective effects of the microbiota in pathological conditions, including infections, inflammatory and
metabolic disorders of multiple body parts, including lungs
(15,16). The host-microbiota symbiosis is sensitive to ge-
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netic makeup, antibiotic use, dietary pattern, allergens, and
infective agents, all of which can alter the microbiota composition. ‘Dysbiosis’, resulting from the host-microbiome
maladjustment, can increase susceptibility or severity of
diseases and multiple health issues concerning the gastrointestinal (GI) and distal sites such as lungs, brain, vagina,
liver, etc. Alteration of the microbiota in gut and lung
has been observed in metabolic and respiratory illnesses
(14), such as inflammatory bowel diseases (IBD), obesity,
type 2 diabetes, cardiovascular disease, Alzheimer’s disease, and depression (17–22). Disturbance in lung microbiota in chronic obstructive airway disease, asthma, tuberculosis, cystic fibrosis, etc. implies the influence of the
lung microbiota in pulmonary health and illnesses (23–
26). Dysbiosis also creates an imbalance in the degree of
activation of leucocytes, leading to lung injury. Gut microbiota modulates the immunity of the lung via the gutlung axis, implying crosstalk between different mucosal
sites of the human body (27). Likewise, the gut-brain axis
presents a bidirectional exchange through neural, humoral,
endocrine, and immune connections, presumed to be mediated by bacterial metabolites such as short-chain fatty acids
(SCFAs) (28). SCFAs modify neuronal excitability, like
the many microbiota-derived neuroactive substances (histamine, acetylcholine, γ -aminobutyric acid, dopamine, and
tryptophan, a precursor in serotonin biosynthesis). Thus,
gut microbiota intervenes in the crosstalk between the central nervous system (CNS) and the enteric nervous system
(ENS), thereby linking brain centers with peripheral intestinal functions for emotional as well as cognitive functions
(28). The role of the gut-brain axis is exemplified by the
dysbiosis associated with CNS diseases and functional GI
disorders.
Gut microbiota is also involved in the pathogenesis of
sepsis and acute respiratory distress syndrome (ARDS)
(29). Depletion of gut microbial diversity can cause dysbiosis, which is therefore attributed to several pathologies.
Geriatrics have reduced the diversity of gut microbiota, including beneficial microbes such as Bifidobacteria species
(30) suggesting microbiotal interaction with the gut-lung
axis. Thus, modulating the microbiome could demonstrate
antiviral effects.
Host-microbiota interactions are bidirectional, complex,
and potentially modulates the development and function
of innate and adaptive immune systems (31,32). Commensals maintain homeostasis by releasing antimicrobial peptides (AMPs) and compete with pathogens for nutrition
and space at the site of infection (33), demonstrating a
mutual relationship between gut microbiota and immune
homeostasis, to be exploited in the current pandemic. Signals by gut microbiota can tune the immune-mediated cells
for proinflammatory (helper T cells type 17; Th17) and
anti-inflammatory (regulatory T cells; Tregs) responses, determining susceptibility to different illnesses (34). Coronavirus infections can be countered by healthy gut micro-
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Figure 1. represents the proposed role of probiotics in the management of COVID-19. Dysbiosis (an altered gut microbial flora) predisposes the individual
to abnormal inflammatory status and increases the susceptibility to the disease. Probiotic supplementation helps to maintain symbiosis in the GIT and
thereby modulate the immune system. The symbiotic state also helps to control the severity of the disease via the gut-lung and gut-brain axes.

biota that protects the lungs and vital organs from an exaggerated immunological response.
Pattern recognition receptors (PRRs) on host cells can
recognize microbe-associated molecular patterns (MAMPs)
and pathogen-associated molecular patterns (PAMPs)
(34,35), possibly generating memory response at primary
exposure. PRRs primarily comprises of the families of
toll-like receptors (TLRs), C-type lectin receptors (CLRs),
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and RIG-I–like receptors (RLRs). TLRs
recognize the MAMPS and PAMPs and induce immunological reactions based on cell type, ligand, or receptor
(35). TLR stimulation by cell wall components and flagellin of gut microbiota is necessary for mounting the immune responses towards influenza. In contrast, oral SCFAinduced anti-inflammatory actions are attributed to decreased pulmonary pathology following bacterial and viral infections in mice (36). Effectively engaging PRRs
expressing innate cells with gut- or non-microbial ligands is essential for the protective mechanism, independent of adaptive immunity during exposure to a pathogen
or secondary infection. The gut microbiota secretes SCFA
metabolites (e.g., acetate, butyrate, and propionate and secondary bile acids) that generate immunomodulatory signals. Commensals such as Lactobacillus, Bacteroides, and
Bifidobacteria bind receptors in dendritic cells (DCs) and
macrophages, subsequently regulating their metabolism
and immune response functions (37). More importantly,

probiotics like Bifidobacterium lactis increased mononuclear leukocytes and antitumour action of natural killer
(NK) cells in healthy geriatric volunteers (38). Balanced
gut microbiota composition significantly impacts the efficiency of the lung immunity of the host (14). Moreover,
germ-free (GF) mice have been found to suffer from impaired pathogen clearance in their lungs (15). Interestingly,
lung infection with influenza virus (IFV) in mice enriches
Enterobacteriaceae and depletes Lactobacilli and Lactococci in the gut microbiota (39).
Microbiota and COVID-19
A pilot study with sequencing faecal samples of 15 patients
showed that COVID-19 infections significantly altered faecal microbiomes characterized by a decline in beneficial
commensals and enrichment of opportunistic pathogens
(40). The baseline abundance of Coprobacillus and few
Clostridium species have been correlated with the severity of COVID-19. Similarly, the abundance of Faecalibacterium prausnitzii, an anti-inflammatory bacterium, was inversely correlated to COVID-19 severity, demonstrating the
influence of SARS-CoV-2 on gut microbiome (40). Similarly, Liu F, et al. and Yeoh YK, et al. reported significant
alterations in the gut microbiome and dysbiosis in COVID
19 patients, associated with disease severity and inflammatory markers (41,42).
Many COVID-19 patients present with GI symptoms
and have sepsis that may originate in the gut (43). GI
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symptoms correlate with profound disease severity. Moreover, angiotensin-converting enzyme 2 (ACE 2) and virus
nucleocapsid protein have been detected in GI epithelial
cells, and virus particles have been isolated from faeces.
Once the virus enters the epithelial cells of GIT and faeces,
COVID-19 patients become highly infectious (44). Since
SARS-CoV-2 binds ACE 2 receptor for its entry into human cells (45), the high expression of angiotensin II receptor type 2 (AT2) cells of the lung, stratified epithelial cells of the esophagus, and absorptive enterocytes of
ileum and colon are critical for infectivity. Bioinformatics data indicate that, like the respiratory system, the GI
system is an important route for SARS-CoV-2 infection
(46). ACE 2 is an essential regulator of intestinal inflammation (46) and significantly influences the composition of
gut microbiota, thereby affecting cardiopulmonary diseases
(47). Pneumonia and subsequent ARDS are critical clinical
manifestations of COVID-19, particularly in geriatric and
immuno-compromised patients (48).
Gou W, et al. suggest that the gut microbiome of healthy
non-infected individuals is highly predictive of the blood
proteomic biomarkers of COVID-19 severity (49). Disruption of the healthy gut microbiome potentially predisposes
healthy individuals to abnormal inflammatory states, possibly accounting for COVID-19 susceptibility and severity.
Restoration of commensal probiotic strains may enhance
the recovery of the lung and the gut via host-derived cytokines and chemokines in addition to microbiota-derived
SCFAs (14). Since human microbiota plays a vital role in
immunomodulation, it can impact SARS-CoV-2 infection.
Current evidence supports the potential role of microbiota
in the susceptibility, progression, and severity of COVID19. Five studies directly connect microbiota with COVID19, supporting the presumptive role of probiotics in both
prevention and treatment of COVID-19 (40–42,49,50)
(Table 1).
Probiotics and Immunity
Food and Agriculture Organization (FAO) under the United
Nations and the World Health Organization (WHO) define probiotics as “live microorganisms, when administered
in adequate amounts, confer a health benefit on the host”
(51). Probiotic formulations are microecological products
that improve the intestinal flora’s architecture, diminish the
growth of harmful microbes, and improve the immune response (51,52). Currently, most extensively researched probiotics include Lactobacillus, Bifidobacteria, Escherichia
coli, Enterococcus, etc. Although probiotics’ mechanism
profoundly focuses on the GIT, the effect of probiotics is
not confined to the initial infection site. Probiotics can act
on the entire body via immune modulation. Probiotics and
their antigenic metabolites are phagocytosed by microfold
cells to form endosomes in gut-associated lymphoid tissues. These antigens are suddenly released and taken in
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by DCs, which can transport them to local lymph nodes
and consequently activate naive T and B cells to differentiate into different effector subpopulations. This initiates
the release of the relevant cytokines and various immune
responses (52).
Pleiotropism of probiotics comprises of strengthening
biological barriers in the intestinal tract and modulating
the equilibrium of intestinal flora. Probiotics provide antimicrobial action, restore intestinal epithelial cell function,
inhibit adhesion and growth of pathogens via a spaceoccupying effect, augment competitive antagonism, secrete
antimicrobial substance like bacteriocins, increase activity of digestive enzymes, and synthesize organic acids,
etc (53). Probiotics increase the expression and release of
mucous glycoproteins via enhanced tight junction proteins
synthesis between epithelial cells, thereby improving epithelial integrity and mechanical barrier function, and preventing the displacement of the intestinal microbes and
endotoxins. Probiotics also initiate repair of damaged barrier function mediated by the tight junction complex reconstruction via enhanced expression and redistribution of
zonula occludens (ZO-2) proteins of the tight junction and
protein kinase C (PKC) (53,54). The introduction of probiotics prevents cytokine-induced epithelial damage, which
is also attributed to mucosal barrier reinforcement. Besides, probiotics enhance mucous secretion, improve barrier function, and pathogen exclusion. Probiotics also prevent pathogen binding by promoting qualitative alterations
in intestinal mucins (53,54). Interestingly, the bacterial
component is also degraded into an AMP, which lends antipathogenic properties to the host. This constitutes an example for an evolutionarily beneficial pleiotropic effect of
large surface proteins. Besides, probiotics also induce the
release of defensins from epithelia, the small peptides active against bacteria, fungi, and viruses. Additionally, these
peptides steady the barrier function of the gut. Probiotics
inhibit the binding of the pathogen via steric hindrance
at pathogen receptors of the enterocyte. Specific metabolites of probiotics modulate signalling and metabolic pathways in different cells. Diverse components of the probiotic metabolome (e.g., hydrogen peroxide, amines, organic
acids, and bacteriocins) interact with multiple targets in
host metabolic pathways that regulate inflammation, angiogenesis, metastasis and cellular proliferation, differentiation, and apoptosis (54).
Probiotics modulate the innate and adaptive immune responses, facilitating the immune system’s development and
maturation. Probiotics regulate host-pathogen interactions
by initiating the innate immune responses that comprise of
TLR, nuclear factor kappa B (NF-κB), mitogen-activated
protein kinase (MAPK), and c-Jun NH2-terminal kinase
(JNK) pathways. Probiotics such as Lactobacillus and
Bifidobacterium can restore host-health by eliminating
pathogens and regulating immune responses in intestinal
epithelial cells. Moreover, probiotics enhance the viability
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Table 1. Studies on association of microbiota with COVID-19 patients
Sl. no.

Author, Year,
place

Study title

Objectives

Method

1.

Gu S, et al.,
(2020), China
(50)

Alterations of the gut
microbiota in patients
with COVID-19 or
H1N1 influenza

To study the gut
microbial flora in
COVID-19, H1N1
patients and healthy
individuals

Prospective
cohort study
(n = 84)

2.

Zuo T, et al.,
(2020), Hong
Kong (40)

Alterations in gut
microbiota of patients
with COVID-19 during
time of hospitalization

To investigate faecal
microbiome in
hospitalised COVID-19
patients

Prospective
cohort study
(n = 15)

3.

Gou W, et al.,
(2020), China
(49)

Gut microbiota may
underlie the
predisposition of
healthy individuals to
COVID-19

4.

Liu F, et al.,
(2021), China
(41)

Gastrointestinal
disturbance and effect
of fecal microbiota
transplantation in
discharged COVID-19
patients

5.

Yeoh YK, et al.,
(2021), Hong
Kong (42)

Gut microbiota
composition reflects
disease severity and
dysfunctional immune
responses in patients
with COVID-19

To identify proteomic
biomarkers that may
indicate predisposition
to COVID-19 in
healthy individuals To
assess influence of gut
microbiota on these
biomarkers in healthy
individuals
To study the effect of
fecal microbiota
transplantation in GI
disturbances, gut
microbiota and
immune system after
SARS-CoV-2 infection
To assess the association
between gut microbiota
and COVID-19 patients

of NK cells and macrophages and stimulate the release of
secretory immunoglobulin A (IgA). As probiotics activate
relevant immune reactions mediated by TLR and NLR,
regulating Th1/Th2 immune responses increase Treg’s
counts that secrete IL-10 and transforming growth factor
(TGF)-β, strengthening their function, thereby decreasing
the antigen-specific IgE levels (53–55). Clinical trials
have demonstrated that certain Bifidobacterium species
could promote the signalling of TGF-β and increase
peripheral Treg cells (56,57). Lactobacillus plantarum
NCU116-induced expression of Th17 and Treg immune
response expresses specific transcription factors like
retinoic acid receptor-related-orphan-receptor-gamma t

Multimethodological
study

Prospective
interventional
study (n = 11)

Prospective
cohort study
(n = 165)

Key Findings
Gut microbiome of COVID-19 and
H1N1 patients were significantly
different from healthy individuals.
An abundance of opportunistic
pathogens and relatively lower
beneficial symbionts were
observed in COVID-19 patients.
H1N1 patients had a lower
diversity and overall different
microbial composition.
Significant alteration in gut
microbiome was seen in
COVID-19 patients. Baseline
microbial composition correlated
with COVID-19 severity. This
dysbiosis persisted even after the
symptoms resolved and virus had
cleared.
Identified 20 blood proteomic
biomarkers and drafted a
proteomic risk score that could
predict severity of COVID-19 in
patients Gut microbial features
were predictive of blood
proteomic markers indicating a
potential biological mechanism on
disease predisposition.
Gut dysbiosis was observed in
patients after SARS-CoV-2
infection. Fecal microbiota
transplantation attenuated GI
symptoms, partially restored gut
microbiome, and significantly
altered B lymphocytes.
Significant alteration in the gut
microbiome was observed in
COVID 19 patients, associated
with disease severity and plasma
concentrations of several
chemokines, cytokines, and
inflammatory markers Significant
decrease in gut microbes with
immunomodulatory properties
were seen in COVID 19 patients.

(RORγ t) and forkhead box protein P3 (FOXP3), in mice.
This strain enhances intestinal mucosal immunity and
modulates Th17/Treg balance, which is attributed to the
TLR pathway in DCs (58).
Probiotics stimulate the immune system, thereby increasing Igs generation, enhancing macrophages and lymphocytes activity, and interferon (IFN)-ɤ stimulation (10).
Probiotics may also inhibit the immune system, primarily embodied in their anti-inflammatory response. Thus,
probiotics have both positive and negative effects on
the immune system. Many immunomodulatory signalling
molecules of the probiotics are MAMPs that interact
with the host cell’s transmembrane PRRs. Immunomod-
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ulation with probiotics attenuate the synthesis of several
cytokines and chemokines and induce anti-inflammatory
molecules, predominantly via TLRs, Th17/Treg, or NFκB signalling pathways. Upon activation by commensals or probiotics, DCs initiate a suitable response like
Th0 to Treg differentiation, which can inhibit Th1, Th2,
and Th17 inflammatory responses. Probiotics can suppress
intestinal inflammation by downregulating TLR expression and the release of metabolites (which inhibit TNFα from entering blood mononuclear cells), thereby inhibiting the signalling of NF-κB in enterocytes (53,54).
Furthermore, both intracellular NLRs, and extracellular
CLRs, can transmit signals through interaction with microbes (52–55). Lactobacillus rhamnosus GR-1 overcomes
Escherichia coli-induced cellular structure destruction and
inflammation, partially by endorsing synergism of TLR2
and nucleotide-binding oligomerization domain-containing
protein 1 (NOD1) and decreasing NLRP3 inflammasome
activation (59). Anti-allergy properties include polarizing
the balance of Th1/Th2 toward a Th1 response, thereby
reducing Th2 cytokines (like IL-4, IL-5, and IL-13) secretion, along with reduced IgE levels and elevated synthesis
of CRP and IgA (60).
Probiotics and Vitamin D
Vitamin D deficiency (VDD) partly explains geographical
differences in COVID-19 susceptibility, severity, and mortality. The immunomodulatory effects of vitamin D suggest
a definitive role of vitamin D in viral infections (55,61).
Vitamin D can also alleviate severe complications and mortality related to COVID-19 and inhibit cytokine storm by
simultaneously boosting the innate immunity and evading
the exaggeration of the adaptive immunity (4). Interestingly, current findings also associate VDD to common comorbidities that increase the severity of COVID-19 such
as certain cancers, autoimmune disorders, diabetes, and
cardiovascular diseases. A well-designed multicentric randomized controlled trial (RCT) with Lactobacillus reuteri
NCIMB 30242 probiotics strain (for nine weeks) increased
serum vitamin D level by 25% (62). Increased vitamin D
levels may be attributed to the probiotic secreting lactic
acid and lowering intestinal pH (Figure 2). When a probiotic was combined with a vitamin D supplement, vitamin
D absorption improved further. Probiotics Lactobacillus
plantarum and Lactobacillus rhamnosus enhanced the expression of vitamin D receptor (VDR) protein and its transcriptional activity, increasing the expression of an AMP,
viz. cathelicidin (63). Probiotics-induced signalling modulation has been demonstrated in VDR knock-out mice in
a salmonella-induced colitis model (64). Probiotics confer both physiological as well as histological protection in
VDR+/+ mice, but not in VDR–/– mice, suggesting that
the probiotic protection in colitis depends on the VDR
pathway. Probiotic supplementation also increases Paneth
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cells, thereby enhancing host defense by secreting AMPs.
Elucidating the probiotics’ mechanism in enhancing VDR
signalling and inhibiting inflammation, makes them an attractive agent for preventing and treating COVID-19 related chronic inflammation (55,61).
Probiotics and Viral Infections
As discussed earlier, protection by probiotics includes
synthesis of antimicrobial agents, immune-modulatory responses, and enhancement of innate host defense. Certain
probiotics also have anti-viral effects, including against
coronavirus (65). Enterococcus faecium inhibits replication
of enteropathogenic coronavirus transmissible gastroenteritis virus (TGEV) in swine testicular cells. This involves
direct interference of virus attachments, adsorptive trapping or virus particle inactivation through surface components of the probiotics and stimulating the synthesis of
pro-inflammatory cytokines IL-6 and IL-8 and nitric oxide
(NO). Probiotics can also interfere with ACE 2, the primary host receptor of the SARS-CoV-2. For instance, during milk fermentation, Lactobacillus helveticus and Lactobacillus casei release peptides with high affinity for ACE.
Bovine milk fermented with Lactobacillus species yields
fermented products enriched with ACE-inhibitory peptides
(66), of which many are resistant to GI digestion and inhibit ACE in the renin-angiotensin system (RAS). In vitro
and in vivo experiments have demonstrated antihypertensive effects of fermented milk products (67,68).
Garcia-Crespo KE, et al. found that intranasal inoculation of Lactobacillus reuteri F275 protects mice from
lethal infection of a pneumonia virus of mice (PVM) (69).
Intranasal Lactobacillus reuteri inoculation prompted immediate and transient neutrophil recruitment along with
pro-inflammatory mediators including chemokine (C-XC motif) ligand (CXCL) 1, CXCL10, chemokine (CC motif) ligand (CCL) 2, CCL3, tumour necrosis factor (TNF)-α and interleukin (IL)-17A, but not Th1 cytokines. Lactobacillus-mediated heterologous immune response warrants investigations into novel antiviral strategies (69). Pre-treatment with Lactobacillus rhamnosus GG
(LGG) in transgenic mice enhanced immune-gene transcription during early IFV infection with upregulation of
type 1 IFN pathways (70). LGG’s protective effect is
mediated via a myeloid differentiation factor (MyD)88dependent mechanism, specifically via TLR4. LGG can
provide early control of IFV and improve transcriptional
responsiveness, acting as a simple and safe strategy to protect neonates. Intranasal LGG also protected mice from infection with IFV by stimulating respiratory cell-mediated
immunity following up-regulation of lung NK cell activation (71). In the LGG-treated mice, lung IL-1β, TNF,
and monocyte chemoattractant protein (MCP)-1 mRNA expression were potentially higher than in control mice. IL1β stimulates the synthesis of IL-2 and affect prolifera-
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Figure 2. Explicit the probable combined/ synergistic effect of probiotics with vitamin D in COVID-19. Probiotic secreting lactic acid will lower the
intestinal pH, thereby increasing the absorption of vitamin D and consequently improves its levels. Certain probiotics enhances the expression of vitamin
D receptor (VDR) protein and its transcriptional activity, subsequently increasing the expression of cathelicidin. Moreover, probiotics also increases the
number of paneth cells, thereby enhancing the levels and expression of defensins.

tion and differentiation of NK cells. Along with IL-12,
TNF works as a co-stimulator for the activation of NK
cells. MCP-1 induces the migration and accumulation of
NK cells in the infected tissue and activates NK. Thus, in
LGG-treated mice, up-regulation of lung IL-1β, TNF, and
MCP-1 mRNA expression may also be attributed to the
stimulation of the lung NK cells. These cells are the major components of the host-nonspecific cell-mediated immune system and take part in recognizing and controlling a broad range of pathogens, including viruses. Previous reports have also proposed that oral administration
of LGG might protect host animals from IFV infection
via interaction with gut-associated immune cells like pancreatic polypeptide (PP) cells, and by direct up-regulation
of respiratory immunity. Intranasal administration of Lactobacillus casei DK128 protected mice from various IFV
subtypes by lowering weight loss and reducing viral loads
(72). Mice protected against primary viral infection with
pretreatment of a probiotic strain developed heterosubtypic
immunity towards secondary virus infection.
Antiviral efficacy of Lactobacillus plantarum DK119
was dose and route dependent (73) and raised the concentration of cytokines IL-12 and IFN-γ in bronchoalveolar lavage fluids of IFV infected mice and was accompanied by diminished inflammation. Modulating innate host
immunity of DC and macrophages, and production of cytokine release patterns could be likely antiviral mechanisms
on IFV. Probiotic treatment enhanced the levels of L-12,
IFN-γ , and reduced inflammatory cytokines such as IL-4,

IL-6, and TNFα in mice. The study concluded that the use
of Lactobacillus plantarum DK119 protected mice from
H1N1 and H3N2 IFV infections, possibly by enhancing the
innate immune response of CD11c+ DC and macrophages
and antiviral cytokines, resulting in the fall of viral loads
in the lungs. Lactobacillus induce human DCs to release
Th1/Th17 cytokines such as TNF-α, IL-12P70, IL-12P40
and IL-23 (74). Moreover, Lactobacillus was reported to
stimulate the synthesis of Th1 polarizing cytokine IL-12 by
inducing murine DCs via TLR 2-dependent mechanisms
(75). The results revealed that specific Lactobacilli trigger
viral defense genes expression in DCs in a TLR 2 dependent manner on IFN-β. Waki N, et al. have shown that
regular consumption of a probiotic drink containing Lactobacillus brevis KB290a decreases incidence of influenza
in 1089 school children, especially in unvaccinated individuals (76).
Lee DK, et al. demonstrated antiviral effect of Bifidobacterium adolescentis SPM 0212 isolated from healthy
Koreans against the hepatitis B virus (HBV) (77). Its
antiviral activity is associated with the Mx-GTPase pathway. The cell extract of the probiotic strain significantly
upregulates gene expression of IFN-signalling components
such as signal transducer and activator of transcription 1
(STAT1) and interferon-induced protein 6–16 gene. Consequently, myxovirus resistance gene A (MxA) expression
improved significantly. MxA protein binds viral nucleocapsids or other viral components and degrade them.
Viruses susceptible to MxA activation are coxsackievirus,
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orthobunyavirus, hantavirus, phlebovirus, dugbe virus,
and HBV. Another study demonstrated that Lactobacillus
ruminis SPM0211, Bifidobacterium longum SPM1205, and
SPM1206 effectively inhibited rotavirus replication in vitro
and in vivo (78). Anti-rotavirus properties of these three
probiotic strains may be attributed to immunomodulatory
response via enhancing type 1 IFNs, key regulators in
the IFN signalling pathway. Selected microbiota strains as
probiotics favour host immunity against viral pathogens
as demonstrated in the treatment of intestinal disorders,
with potential promise in respiratory diseases including
COVID-19.
Probiotics and COVID-19: Current Perspectives
A few reports cite indirect evidence for the association between probiotics and COVID-19, mostly based on previous
coronavirus and other viral infections. A systematic review
by Pourhossein M, et al. described the probiotics’ efficacy
against viral diseases, where more than 20 strains improved
the anti-inflammatory ILs and antibody production against
viruses (79). Moreover, viral loads were lowered upon probiotic supplementation, possibly via immune modulation
by microbiota that fights COVID-19 directly and decreases
the risk of secondary infections due to prolonged antibiotic exposure from multiple experimental COVID-19 treatments (80). China’s National Health Commission recommended probiotics for severe COVID-19 patients to restore
the intestinal balance and protect from secondary infections. Moreover, gut microbiota’s role in modulating lung
diseases has been amply demonstrated. Diminished diversity of gut microbiota in the elderly might be causally
related to higher COVID-19 fatality. Taxonomic changes
and ageing have been correlated with decreased metabolic
potential of microbiome, including diminished generation
of SCFAs (30). Improving gut microbiota profile by probiotic supplements could, therefore, enhance immunity, suggesting a possible prophylactic strategy in geriatrics and
immunocompromised people.
SARS-CoV-2 compromises lung function via binding
of ACE 2 receptors on the alveolar epithelial cells. However, viral RNA was recently detected in the faeces of
COVID-19 patients (43,44). Indeed, the intestinal epithelial cells, predominantly the small intestinal enterocytes,
also express ACE 2 receptors that are critically involved
in cardiovascular physiology, pathology, and acute lung injury, including ARDS. ACE 2 is an important regulator of
intestinal inflammation. Moreover, there is a wide disparity in COVID susceptibility and disease progression. Gou
W, et al. suggest that susceptibility among diverse cohorts
might be related to composition of microbiota (49). The
faecal metabolites suggest that an amino acid-related pathway may provide the key link between the core gut microbiota, inflammation, and COVID-19 susceptibility. The
core gut microbial features and related metabolites may
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serve as potential preventive/ treatment targets for intervention, especially among susceptible populations (34).
A report from China suggests that COVID-19 patients
suffer microbial dysbiosis with depleted Lactobacillus and
Bifidobacterium, with over 60% of patients expressing GI
symptoms such as diarrhoea, nausea, and vomiting (81). GI
symptoms also imply greater severity. Around 58–71% of
COVID-19 patients were administered antibiotics in China,
and diarrhoea was reported in 2–36% of them. Reinforcement of colonic microflora using probiotics diminishes secondary infection and diarrhoea in patients receiving antibiotics. A meta-analysis by Kang EJ, et al. revealed that probiotics such as Lactobacillus and Bifidobacterium produce
a modest decrease in common cold, a symptom of SARSCoV-2 infection (82). In these studies, probiotic supplementation either decreased the severity or shortened the duration of disease 2–47% of COVID-19 patients need invasive mechanical ventilation due to development ARDS. A
meta-analysis of RCTs suggests that probiotics decreased
ventilator-associated pneumonia (VAP) (83) and reduced
the duration of antibiotic use for VAP.
COVID-19 is a multi-organ phenomenon, requiring appropriate systemic inflammatory control for overall survival. Besides, COVID-19 infection expresses new presentations, such as pediatric multisystem inflammatory syndrome, which includes features like Kawasaki disease (84).
‘Cytokine storm’ or the excessive release of inflammatory
cytokines is the reason for severity and death of COVID-19
patients (4). Therefore, anti-cytokine therapy for the suppression of the hyperinflammatory states is a recommended
strategy to treat severe COVID-19. So far, many preclinical studies with probiotics have focused on influenza and
pneumonia, demonstrating benefits from oral or nasal administration of probiotics, which prolonged survival, reduced weight loss, diminished viral loads in the lung, and
minimized bronchial epithelial damage (70–73). Protection was mediated by immune regulation, distinguished by
potent viricidal properties by early recruitment of innate
immune system through alveolar macrophages, NK lymphocytes and heightened proinflammatory cytokines such
as TNF-α and IL-6, etc. This inflammatory boost is followed by a rapid decline, attributed to enhanced antiinflammatory mediators like Treg cells and IL-10 in the
lungs, diminishing lung injuries (14). Moreover, probiotics’
ability to modulate vitamin D/VDR and balancing the composition and growth of gut microbiota (34), together suggest the immunomodulatory potential in ameliorating the
cytokine storm. Therefore, the use of probiotics with antiinflammatory effects could maintain the equilibrium of intestinal microecology and prevent secondary infection in
COVID-19.
Most importantly, the current pandemic is particularly
severe, with higher case fatality in individuals with noncommunicable diseases (NCDs). 20–51% of COVID-19
patients suffered at least one comorbidity, like diabetes
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(10–20%), hypertension (10–15%), and cardio-and cerebrovascular diseases (7–40%) (85). Many studies and
anecdotal reports suggest obesity as a notable risk factor for COVID-19, primarily in younger patients (86).
Moreover, people with diabetes need a balanced diet to
control glycemia and maintain immune function. However,
hypo-nutrition aggravates impaired immunity in COVID19 (87). On the other hand, probiotics may reduce cardiovascular and diabetes risk factors such as elevated blood
pressure, serum cholesterol, obesity, and insulin resistance.
Growing evidence reveals that probiotics can lower elevated blood pressure, glycemia, low-density lipoproteins
(LDL)-cholesterol, LDL/high-density lipoproteins (HDL)
ratio, inflammatory mediators, and body mass index (88).
Modulating the gut microbiota composition by probiotics
modify central energy metabolism and alter satiety hormone levels, exerting anti-obesity effects. A study in mice
demonstrated that a carboxypeptidase derived from Paenibacillus sp.B38 suppressed angiotensin-II-induced hypertension, cardiac hypertrophy, and fibrosis (89). COVID-19
frequently presents with coagulopathy and thrombotic
complications. COVID-19 associated coagulopathy (CAC),
is emerging as a key survival indicator in SARS-CoV-2 infection (90). The probiotic lactic acid bacteria (LAB) can
produce a beneficial effect during IFV, respiratory syncytial
virus, and Streptococcus pneumonia infection via modulating the immunocoagulative response in the host (91).
Zelaya H, et al. demonstrated that Lactobacillus rhamnosus
CRL1505 administered nasally in adult immunocompetent
mice, significantly modulates inflammation, maintains
homeostasis, and decreases lung tissue damage after pneumococcal infection (91). The induction of IFN-γ , IL-10,
and von Willebrand factor (vWF) via the TLR 2 signalling
pathway appears to have a vital role in the ‘immunobiotic’
effect of probiotic strains. The probiotics enhance the
release of TNF-α, IFN-γ , and IL-10 during pneumococcal
infection and reduce tissue factor (TF). Immunobiotic
therapy significantly decreases the permeability of the
bronchoalveolar-capillary barrier, reducing lung damage,
and general cytotoxicity. Therefore, corrective measures of
immunomodulation, including probiotic supplementation,
can reinstate innate and adaptive immunity, offering a
promising therapeutic adjunct for COVID-19 (92).
Neurological manifestations of COVID-19 are mounting
in parallel with the expanding pandemic (93). These could
be direct effects of SARS-CoV-2 on the nervous system,
para- or post-infectious immune-mediated illness, and neurological complications of the systemic impacts of COVID19. A UK-wide surveillance study reported psychiatric or
neurological disorders in 125 COVID-19 patients, with
altered mental status (39;31%), including encephalopathy
(16;13%) and neuropsychiatric illness (23;18%) such as
psychosis (10; 8%), neurocognitive (dementia-like) syndrome (6;5%), and an affective disorder (4;3%) (94). Remarkably, the patient data showed cerebrovascular event

(77;62%) including ischaemic strokes (57;46%), intracerebral haemorrhages (9;7%), CNS vasculitis (1;<1%), and
other cerebrovascular events (10;8%). The significant role
of probiotics in the prevention and treatment of neurologic
disorders involves multiple pathways such as neural, immunological, and metabolic via the brain-gut axis. Preclinical evidence shows probiotics have neuroprotective effects
against ischemic/reperfusion injury, possibly via antioxidant and antiapoptotic effects, anxiolytic effects, improved
cognition, attenuation of inflammatory response and elevated serotoninergic precursors and antidepressant effects
(95). Indeed, in an RCT, the oral administration of Lactobacillus helveticus R0052 and Bifidobacterium longum
R0175, for one month, decreased psychological distress
and depression in healthy volunteers (96). Likewise, in
another RCT, fermented milk with Bifidobacterium animalis subsp. lactis, Streptococcus thermophiles, Lactobacillus bulgaricus and Lactococcus lactis subsp. lactis
affected regions of the brain that regulate the central processing of emotion and sensation in healthy women (97).
Similarly, oral administration of Lactobacillus casei strain
Shirota for two months in chronic fatigue syndrome reduced anxiety significantly more than controls. Probiotic
metabolites can interact with and play a role in behaviour.
Dinan TG, et al. (98) showed that physical or psychological stress is directly associated with the microbiota-braingut axis imbalance. Moreover, probiotics also diminish the
frequency and severity of migraine headache attacks (99).
We found 14 RCTs and one prospective observational
study with probiotics registered in clinical trial registries
around the world (Supplementary Table1).
Conflicting Evidence on Probiotics
Differences persist in the physiology and metabolism
among probiotic strains of various species, and consequently, their effects are different on the human body. Even
different strains of the same species may have different
health effects (100). The dose also matters, and a probiotic
consumed at a higher dose may not be as good as a lower
dose. Similarly, different doses of the same probiotic strain
can produce diverse effects. Besides, the same probiotic
strain can function differently in different hosts. Hence,
the functions of probiotics should be proved at the strain
level to confirm efficacy. Therefore, probiotics should be
cautiously selected for optimal benefit.
There have been adverse reports of probiotics. According to Single-cell RNA sequencing (scRNA-Seq) analysis,
Feng Z, et al. (101) demonstrated the ACE2, SARS-Cov-2
receptor, could be elevated in the presence of both invasive
bacteria Salmonella enterica and its counterpart, Segmented Filamentous Bacteria as probiotics in the mouse
small intestine (102) and human enterocytes (101). In
another study, both Lactobacillus acidophilus and Bacillus
clausii also failed to decrease the expression of coronavirus
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receptors compared to control after Salmonella infection
in the murine intestine (103). The efficacy, as well as
the safety of probiotics, have been contentious. Although
adverse effects of probiotics appear to be mild (mainly
digestive belching or bloating), severe consequences have
been noticed in individuals with underlying health issues.
There are reports of fungaemia (104) and bacteraemia
(105) following probiotic administration. A Salmonellacolitis mice model has demonstrated that probiotic therapy
in the absence of VDR expression produce severe infection (106). The dependence of probiotic function on VDR
status, may explain the disparity in the clinical response
of some IBD patients. The rationale for introducing
probiotics for COVID-19 comes from indirect evidence
(107). Therefore, blindly using conventional probiotics is
not warranted until we clearly understand SARS-CoV-2
pathogenesis, its effect on gut microbiota, and vice-versa.
Conclusion
Evidence supports probiotics’ role in regulating the immune system, suggesting a definitive role for probiotics
in viral infections. Probiotics supplementation could reduce the severity of COVID-19 morbidity and mortality.
Probiotics can inhibit cytokine storm by simultaneously
boosting the innate immunity and evading the exaggeration of adaptive immunity, which is challenged to respond
quickly to the viral onslaught. Probiotics-induced suppression of the inflammatory cytokine response may prevent
both the severity and the occurrence of ARDS, making
probiotics an attractive adjunct. Inventing effective therapy will transform the impact of the pandemic on lives as
well as economies across the globe. Therefore, supplementation of probiotics in high risk and severely ill patients,
and frontline health workers, might limit the infection and
flatten the COVID-19 curve. However, currently, there are
no RCTs to demonstrate conclusive evidence. On the other
hand, circumstantial evidence has supported the presumption that probiotic supplementation decreases the severity
of COVID-19 responses, including mortality. Many clinical trials are underway globally to delineate the role of
probiotics in both prevention and treatment of COVID-19.
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